{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T12:26:14Z","timestamp":1792844774988,"version":"4.5.0"},"reference-count":37,"publisher":"American Society of Hematology","issue":"3","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,1,16]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Monoclonal gammopathy of undetermined significance (MGUS) is an asymptomatic premalignant disorder. The current standard of care is not to screen for MGUS, so it is often incidentally diagnosed in the clinic. It is unknown whether the outcomes of screened vs clinically detected MGUS differ. We compared the progression risk between screened vs clinical MGUS cohorts and assessed whether the MGUS detection method affected risk prediction of established clinical factors (score). We included 379 screened MGUS cases from the Olmsted County population-based study and 1384 patients with MGUS diagnosed during routine clinical evaluation at Mayo Clinic. Median follow-up time for the screened vs clinical cohort was 26.6 and 40.1 years, respectively. Accounting for death as a competing risk, the cumulative incidence of progression at 25 years was similar in the screened (11.1% [95% confidence interval [CI], 8.3-14.8]) vs clinical (10.1% [95% CI, 8.6-11.8]) MGUS cohorts, even when stratified by sex, age, or the baseline MGUS risk score. Overall, 0.9 (95% CI, 0.6-1.2) of patients with screened MGUS vs 1.0 (95% CI, 0.9-1.2) of those with clinically detected MGUS experienced disease progression for every 100 person-years of follow-up. MGUS detection method did not modify the association between MGUS risk score and progression risk (pinteraction\u00a0=\u00a00.217) and did not add to known risk factors for progression (likelihood ratio test; P\u00a0=\u00a0.839). Here, we show that progression risk among patients with screened vs clinically detected heavy-chain MGUS was similar. Future studies are needed to assess whether tailored follow-up of patients with screened MGUS affects clinical outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2024025415","type":"journal-article","created":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T18:03:09Z","timestamp":1729620189000},"page":"325-333","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":18,"title":["Comparison of progression risk of monoclonal gammopathy of undetermined significance by method of detection"],"prefix":"10.1182","volume":"145","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7201-4642","authenticated-orcid":false,"given":"Alissa","family":"Visram","sequence":"first","affiliation":[{"name":"1Division of Hematology, Ottawa Hospital Research Institute, The Ottawa Hospital, Ottawa, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2970-2124","authenticated-orcid":false,"given":"Dirk","family":"Larson","sequence":"additional","affiliation":[{"name":"2Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Norman","sequence":"additional","affiliation":[{"name":"2Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8780-9512","authenticated-orcid":false,"given":"Angela","family":"Dispenzieri","sequence":"additional","affiliation":[{"name":"3Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Murray","sequence":"additional","affiliation":[{"name":"4Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Kyle","sequence":"additional","affiliation":[{"name":"3Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Vincent","family":"Rajkumar","sequence":"additional","affiliation":[{"name":"3Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5173-4712","authenticated-orcid":false,"given":"Susan","family":"Slager","sequence":"additional","affiliation":[{"name":"2Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN"},{"name":"3Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5392-9284","authenticated-orcid":false,"given":"Shaji","family":"Kumar","sequence":"additional","affiliation":[{"name":"3Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1962-9322","authenticated-orcid":false,"given":"Celine","family":"Vachon","sequence":"additional","affiliation":[{"name":"2Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"12","key":"2025011616203222400_bib1","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"issue":"13","key":"2025011616203222400_bib2","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1056\/NEJMoa054494","article-title":"Prevalence of monoclonal gammopathy of undetermined significance","volume":"354","author":"Kyle","year":"2006","journal-title":"N\u00a0Engl J Med"},{"issue":"suppl 1","key":"2025011616203222400_bib3","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1182\/blood-2021-152333","article-title":"Screening for monoclonal gammopathy of undetermined significance: a population-based randomized clinical trial. First results from the Iceland screens, treats, or prevents multiple myeloma (iStopMM) study","volume":"138","author":"Kristinsson","year":"2021","journal-title":"Blood"},{"issue":"5","key":"2025011616203222400_bib4","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/j.mayocp.2019.12.033","article-title":"Monoclonal gammopathy of undetermined significance: indications for prediagnostic testing, subsequent diagnoses, and follow-up practice at Mayo Clinic","volume":"95","author":"Ravindran","year":"2020","journal-title":"Mayo Clin Proc"},{"issue":"6","key":"2025011616203222400_bib5","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1038\/leu.2010.60","article-title":"Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management","volume":"24","author":"Kyle","year":"2010","journal-title":"Leukemia"},{"issue":"3","key":"2025011616203222400_bib6","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.clml.2014.09.004","article-title":"Determining the clinical significance of monoclonal gammopathy of undetermined significance: a SEER-Medicare population analysis","volume":"15","author":"Go","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"22","key":"2025011616203222400_bib7","doi-asserted-by":"crossref","first-page":"5418","DOI":"10.1182\/blood-2008-12-195008","article-title":"A\u00a0monoclonal gammopathy precedes multiple myeloma in most patients","volume":"113","author":"Weiss","year":"2009","journal-title":"Blood"},{"issue":"22","key":"2025011616203222400_bib8","doi-asserted-by":"crossref","first-page":"5412","DOI":"10.1182\/blood-2008-12-194241","article-title":"Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study","volume":"113","author":"Landgren","year":"2009","journal-title":"Blood"},{"issue":"2","key":"2025011616203222400_bib9","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41408-019-0172-1","article-title":"Patients with precursor disease exhibit similar psychological distress and mental HRQOL as patients with active myeloma","volume":"9","author":"Maatouk","year":"2019","journal-title":"Blood Cancer J"},{"issue":"1","key":"2025011616203222400_bib10","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/j.1365-2141.2010.08207.x","article-title":"Monoclonal gammopathy of undetermined significance: a consensus statement","volume":"150","author":"Berenson","year":"2010","journal-title":"Br J Haematol"},{"issue":"1","key":"2025011616203222400_bib11","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/j.1365-2141.2009.07807.x","article-title":"UK Myeloma Forum (UKMF) and Nordic Myeloma Study Group (NMSG): guidelines for the investigation of newly detected M-proteins and the management of monoclonal gammopathy of undetermined significance (MGUS)","volume":"147","author":"Bird","year":"2009","journal-title":"Br J Haematol"},{"issue":"6","key":"2025011616203222400_bib12","doi-asserted-by":"crossref","first-page":"984","DOI":"10.3324\/haematol.2013.100552","article-title":"The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma Network","volume":"99","author":"Van De Donk","year":"2014","journal-title":"Haematologica"},{"issue":"5","key":"2025011616203222400_bib13","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41408-021-00480-w","article-title":"Iceland screens, treats, or prevents multiple myeloma (iStopMM): a population-based screening study for monoclonal gammopathy of undetermined significance and randomized controlled trial of follow-up strategies","volume":"11","author":"R\u00f6gnvaldsson","year":"2021","journal-title":"Blood Cancer J"},{"issue":"3","key":"2025011616203222400_bib14","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa1709974","article-title":"Long-term follow-up of monoclonal gammopathy of undetermined significance","volume":"378","author":"Kyle","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"2025011616203222400_bib15","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1182\/bloodadvances.2020003193","article-title":"Rheumatologic diseases impact the risk of progression of MGUS to overt multiple myeloma","volume":"5","author":"Steiner","year":"2021","journal-title":"Blood Adv"},{"issue":"12","key":"2025011616203222400_bib16","first-page":"1697","article-title":"Respiratory tract infections in the pathway to multiple myeloma: a population-based study in Scandinavia","volume":"91","author":"Landgren","year":"2006","journal-title":"Haematologica"},{"issue":"7","key":"2025011616203222400_bib17","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1002\/ijc.28479","article-title":"Common community-acquired infections and subsequent risk of multiple myeloma: a population-based study","volume":"134","author":"McShane","year":"2014","journal-title":"Int J Cancer"},{"issue":"12","key":"2025011616203222400_bib18","doi-asserted-by":"crossref","first-page":"3392","DOI":"10.3324\/haematol.2023.283191","article-title":"Disease associations with monoclonal gammopathy of undetermined significance can only be evaluated using screened cohorts: results from the population-based iStopMM study","volume":"108","author":"Sigurbergsd\u00f3ttir","year":"2023","journal-title":"Haematologica"},{"issue":"3","key":"2025011616203222400_bib19","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1182\/blood-2005-03-1038","article-title":"Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance","volume":"106","author":"Rajkumar","year":"2005","journal-title":"Blood"},{"issue":"9","key":"2025011616203222400_bib20","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1093\/clinchem\/48.9.1437","article-title":"Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light\u00a0chains","volume":"48","author":"Katzmann","year":"2002","journal-title":"Clin Chem"},{"issue":"7","key":"2025011616203222400_bib21","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1182\/blood-2007-05-088443","article-title":"New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells","volume":"110","author":"P\u00e9rez-Persona","year":"2007","journal-title":"Blood"},{"issue":"2","key":"2025011616203222400_bib22","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1002\/ajh.23355","article-title":"Immunoparesis and monoclonal gammopathy of undetermined significance are disassociated in advanced age","volume":"88","author":"Cherry","year":"2013","journal-title":"Am J Hematol"},{"issue":"1","key":"2025011616203222400_bib23","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1038\/leu.2012.189","article-title":"Suppression of uninvolved immunoglobulins defined by heavy\/light chain pair suppression is a risk factor for progression of MGUS","volume":"27","author":"Katzmann","year":"2013","journal-title":"Leukemia"},{"issue":"3","key":"2025011616203222400_bib24","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1182\/blood-2013-05-505487","article-title":"Monoclonal gammopathy of undetermined significance and risk of lymphoid and myeloid malignancies: 728 cases followed up to 30 years in Sweden","volume":"123","author":"Turesson","year":"2014","journal-title":"Blood"},{"issue":"12","key":"2025011616203222400_bib25","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1182\/bloodadvances.2021006201","article-title":"Prevalence of heavy chain MGUS by race and\u00a0family history risk groups using a high-sensitivity screening method","volume":"6","author":"Vachon","year":"2022","journal-title":"Blood Adv"},{"issue":"5","key":"2025011616203222400_bib26","doi-asserted-by":"crossref","first-page":"e340","DOI":"10.1016\/S2352-3026(22)00069-2","article-title":"Prevalence of monoclonal gammopathies and clinical outcomes in a high-risk US population screened by mass spectrometry: a multicentre cohort study","volume":"9","author":"El-Khoury","year":"2022","journal-title":"Lancet Haematol"},{"issue":"12","key":"2025011616203222400_bib27","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/s41408-019-0263-z","article-title":"Detection\u00a0and prevalence of monoclonal gammopathy of undetermined significance: a\u00a0study utilizing mass spectrometry-based monoclonal immunoglobulin rapid accurate mass measurement","volume":"9","author":"Murray","year":"2019","journal-title":"Blood Cancer J"},{"issue":"9727","key":"2025011616203222400_bib28","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1016\/S0140-6736(10)60482-5","article-title":"Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study","volume":"375","author":"Dispenzieri","year":"2010","journal-title":"Lancet"},{"issue":"9","key":"2025011616203222400_bib29","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41408-022-00732-3","article-title":"Defining new reference intervals for serum free light chains in individuals with chronic kidney disease: results of the iStopMM study","volume":"12","author":"Long","year":"2022","journal-title":"Blood Cancer J"},{"issue":"3","key":"2025011616203222400_bib30","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1182\/blood-2005-08-3449","article-title":"Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States","volume":"107","author":"Landgren","year":"2006","journal-title":"Blood"},{"issue":"12","key":"2025011616203222400_bib31","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1016\/S0025-6196(11)61089-6","article-title":"Prevalence of monoclonal gammopathy of undetermined significance among men in Ghana","volume":"82","author":"Landgren","year":"2007","journal-title":"Mayo Clin Proc"},{"issue":"10","key":"2025011616203222400_bib32","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1038\/leu.2009.134","article-title":"Patterns of monoclonal gammopathy of undetermined significance and multiple myeloma in various ethnic\/racial groups: support for genetic factors in pathogenesis","volume":"23","author":"Landgren","year":"2009","journal-title":"Leukemia"},{"issue":"12","key":"2025011616203222400_bib33","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1158\/1055-9965.EPI-22-0525","article-title":"Prevalence of monoclonal gammopathy of undetermined significance in Black South African men","volume":"31","author":"Cicero","year":"2022","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"8","key":"2025011616203222400_bib34","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1182\/blood-2008-06-162768","article-title":"Risk of lymphoproliferative disorders among first-degree relatives of lymphoplasmacytic lymphoma\/Waldenstrom macroglobulinemia patients: a population-based study in Sweden","volume":"112","author":"Kristinsson","year":"2008","journal-title":"Blood"},{"issue":"12","key":"2025011616203222400_bib35","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1002\/ijc.21745","article-title":"Familial characteristics of autoimmune and hematologic disorders in 8,406 multiple myeloma patients: a population-based case-control study","volume":"118","author":"Landgren","year":"2006","journal-title":"Int J Cancer"},{"issue":"4","key":"2025011616203222400_bib36","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1182\/blood-2008-12-192575","article-title":"Increased risk of monoclonal gammopathy in first-degree relatives of patients with multiple myeloma or monoclonal gammopathy of undetermined significance","volume":"114","author":"Vachon","year":"2009","journal-title":"Blood"},{"issue":"4","key":"2025011616203222400_bib37","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1111\/j.1365-2141.2012.09075.x","article-title":"Increased prevalence of light chain monoclonal gammopathy of undetermined significance (LC-MGUS) in first-degree relatives of individuals with multiple myeloma","volume":"157","author":"Greenberg","year":"2012","journal-title":"Br J Haematol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/145\/3\/325\/2351610\/blood_bld-2024-025415-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/145\/3\/325\/2351610\/blood_bld-2024-025415-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T11:20:48Z","timestamp":1737026448000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/145\/3\/325\/518285\/Comparison-of-progression-risk-of-monoclonal"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,16]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,1,16]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2024025415","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,16]]}}}